P+P Pöllath + Partners advises Zur Rose Group on the acquisition of TeleClinic

Munich — The Zur Rose Group has acqui­red Tele­Cli­nic GmbH (“Tele­Cli­nic”), based in Munich, for a purchase price in the mid double-digit million euro range.

Tele­Cli­nic was foun­ded in 2015 by Katha­rina Jünger and has quickly estab­lished itself as the leading tele­me­di­cine provi­der in Germany. The company provi­des tele­me­di­cine services, inclu­ding digi­tal prescrip­ti­ons and dise­ase certi­fi­ca­tes that are compli­ant with German health insu­rance reim­bur­se­ment regu­la­ti­ons. After a diagno­sis by a specia­list, pati­ents who are self-paying receive an e‑prescription based on a Tele­Cli­nic solu­tion via app on their cell phone, which they can redeem at an on-site or mail-order phar­macy. Online sick notes can be sent directly to the employer via email. Doctors can join the plat­form easily and without obli­ga­tion and offer their exper­tise flexi­bly and regard­less of location.

The Swiss Zur Rose Group is Europe’s largest e‑commerce phar­macy and one of the leading medi­cal whole­sa­lers in Switz­er­land. It also opera­tes the leading market­place in Southern Europe for phar­­macy-bran­­ded health and perso­nal care products. The company has an inter­na­tio­nal presence, inclu­ding Germany’s best-known phar­macy brand DocMor­ris. Zur Rose employs more than 1,800 people at its sites in Switz­er­land, Germany, the Nether­lands, Spain and France. In 2019, it gene­ra­ted sales of 1,569 million Swiss francs (inclu­ding medpex) at

Advi­sor Zur Rose Group: P+P Pöllath + Partners 
Dr. Michael Inhes­ter (Part­ner, Lead Part­ner, M&A, Munich)
Adal­bert Makos (Coun­sel, M&A, Munich)
Daniel Wied­mann, LL.M. (NYU) (Asso­cia­ted Part­ner, Anti­trust Law, Frankfurt)
Matthias Ober­bauer (Asso­ciate, M&A, Munich)